Welcome Biosensor’s digital booth!

The Biosensors International Group Ltd (Biosensors) develops, manufactures and markets innovative and pioneering interventional cardiology devices.

Biosensors developed and patented their own highly lipophilic, limus agent Biolimus A9™ with properties that would support healing and re-endothelialization, specifically designed for coronary stent technologies.
In 2012 Biosensors began studying High Bleeding Risk (HBR) patients, with only one month of ultra-short DAPT mandated for all patients, regardless of clinical presentation. To date 14 publications from their landmark clinical trial program in this patient population, making them the High Bleeding Risk Experts!
Recently Biosensors’ parent company made a significant investment into the rapidly growing field of structural heart disease intervention through the acquisition of New Valve Technology (NVT), the developers of the flagship product Allegra™ transfemoral TAVI system.

Together, Biosensors and NVT will leverage their respective innovative expertise in Cardiovascular and Structural Heart technologies.

    • By filling this form, I consent to and acknowledge Com&Co's confidentiality policy.

Contact

José Ignacio Martinez Arbués
Director Iberia, Switzerland & Benelux
Tel: +34 629176255 │ email: i.martinez@biosensors.com

Biosensors Europe SA
Rue de Lausanne 29
1110 Morges, Switzerland
Tel: +41 (0) 21 804 8000